NCT00423189View on ClinicalTrials.gov

Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration

PHASE4TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Age-Related Macular Degeneration
Interventions
DRUG

Ranibizumab (Lucentis)

as needed, one intravitreal injection of 0.50mg ranibizumab

DRUG

0.5mg ranibizumab

as needed, one intravitreal injection of 0.50mg ranibizumab

Trial Locations (1)

77030

Vitreoretinal Consultants, Houston

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

David M. Brown, M.D.

OTHER